About this site
A due-diligence reading desk on the semaglutide record
What this project is, what the "legal" in the name means, and what it deliberately is not.
What this project is
Semaglutide Legal keeps a due-diligence file on semaglutide: a calm, plain-English reading of the peer-reviewed trial record and the public regulatory history, with every quantitative claim attributed. The file offers no diagnosis, no medical advice, and no legal opinion; there is no clinic, no clinician, and no product for sale behind it — only the record, read closely. Reading the published science and citing it is the whole remit.
The purpose is narrow and consistent: take the registrational trial record — STEP, SUSTAIN, SELECT, FLOW, ESSENCE, SURMOUNT-5 — and the approved-label facts, and render them calmly and accurately for a general reader, with every quantitative claim attributed. The site leads with the kidney-outcomes evidence because that is the lens it was built around.
What the "legal" in the name means
The "legal" modifier is editorial framing, not a claim that this site offers legal services or legal advice. It signals the angle the publisher takes toward the literature: a regulatory-due-diligence reading that foregrounds approval status, labeled indications, and the distinction between the approved manufactured product and compounded preparations.
We summarize the public regulatory record — that semaglutide is FDA-approved across several indications, and that compounding was permitted during a declared shortage and curtailed once it resolved. We do not interpret anyone's individual legal situation, and nothing on this site should be read as legal advice. It is a reading desk on what the record says, not a substitute for a lawyer or a clinician.
How we work
Every page is built from a curated set of peer-reviewed sources, listed in full on the references page. Quantitative claims — percentages, hazard ratios, doses, half-lives — are tied to a numbered citation with a DOI or PubMed link. We use generic compound names only and avoid brand names entirely.
We describe what the studies measured, in the third person, and we keep reported real-world effects clearly separated from clinical findings and clearly labeled as anecdotal. We do not recommend doses, and we do not tell anyone whether to use this or any medicine. Where the evidence is uncertain or a signal is unconfirmed, we say so rather than smoothing it over.
What this site is not
This site is not a pharmacy, a vendor, a telehealth service, or a clinic, and it has no physical location, no phone line, and no clinical staff. It does not sell semaglutide or any other product and will not direct readers to a source for it.
The modifier in the domain name is a publisher's editorial position relative to the literature, not a description of services offered. If you are making decisions about your own health, that is a conversation for a licensed clinician who knows your history — not for a reading desk. Our role ends at summarizing the published science clearly and citing it honestly.